{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:57:16Z","timestamp":1790870236447,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":245,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02554"],"award-info":[{"award-number":["24K02554"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphocyte activation gene 3 (LAG3) has emerged as a clinically actionable immune checkpoint target in oncology, but its molecular determinants in glioma remain poorly characterized. We aimed to determine whether TP53 mutation is associated with LAG3 expression, whether this is selective among immune checkpoint genes, and whether it persists after adjustment for transcriptomic immune scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed gene expression and mutation data from the Genomic Data Commons (GDC), incorporating three datasets (TCGA, CPTAC, HCMI) into a GDC discovery cohort of WHO grade 4 glioma (n\u2009=\u2009442). An independent Glioma Longitudinal Analysis (GLASS) dataset served as a validation cohort (n\u2009=\u200979). LAG3 and 6 additional checkpoint genes were compared between TP53-mutant and wild-type tumors using Wilcoxon rank-sum tests and adjusted linear regression with transcriptomic immune scores as covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TP53 mutation was consistently associated with elevated LAG3 expression in the GDC cohort (median difference = +0.288 log2(TPM + 1), Cliff\u2019s \u03b4 \u2009=\u2009 0.289, P\u2009=\u20097.13\u2009\u00d7\u200910\u20137) and replicated in the GLASS cohort (\u03b4 \u2009=\u2009 0.395, P\u2009=\u2009.005). Among 7 checkpoint genes, only LAG3 showed significant TP53-associated upregulation after Benjamini\u2013Hochberg correction in both cohorts. The TP53 regression coefficient was unchanged after immune score adjustment, and TP53 status was not associated with any immune score (all P\u2009\u2265\u2009.67). Adjustment for tumor purity and proliferation-related Hallmark programs partially attenuated but did not abolish the association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TP53 mutation is associated with selective, immune context-independent LAG3 upregulation in grade 4 glioma, supporting TP53 mutation as a candidate stratifier for LAG3-targeted immunotherapy and motivating mechanistic studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag233","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:35:46Z","timestamp":1788449746000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>TP53<\/i>\n                    mutation is associated with selective upregulation of\n                    <i>LAG3<\/i>\n                    independent of immune infiltration and antigen-presentation signatures in WHO grade 4 glioma"],"prefix":"10.1093","volume":"8","author":[{"given":"Youji","family":"Uemae","sequence":"first","affiliation":[{"name":"Cell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki, 305-0047, (Y.U., T.O.)","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Miki","sequence":"additional","affiliation":[{"name":"University of Tsukuba, Department of Neurosurgery, Institute of Medicine, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, (S.M., E.Y., E.I.)","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Yamada","sequence":"additional","affiliation":[{"name":"University of Tsukuba, Department of Neurosurgery, Institute of Medicine, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, (S.M., E.Y., E.I.)","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zaboronok","sequence":"additional","affiliation":[{"name":"University of Tsukuba, Department of Neurosurgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, (A.Z.)","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ohno","sequence":"additional","affiliation":[{"name":"Cell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki, 305-0047, (Y.U., T.O.)","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-9767","authenticated-orcid":false,"given":"Eiichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"University of Tsukuba, Department of Neurosurgery, Institute of Medicine, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, (S.M., E.Y., E.I.)","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026100111161357000_vdag233-B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100111161357000_vdag233-B2","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026100111161357000_vdag233-B3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026100111161357000_vdag233-B4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100111161357000_vdag233-B5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"2026100111161357000_vdag233-B6","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J Immunol"},{"key":"2026100111161357000_vdag233-B7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat Immunol"},{"key":"2026100111161357000_vdag233-B8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"2026100111161357000_vdag233-B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"2026100111161357000_vdag233-B10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100111161357000_vdag233-B11","doi-asserted-by":"publisher","first-page":"EVIDoa2200239","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"key":"2026100111161357000_vdag233-B12","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/j.1349-7006.2007.00518.x","article-title":"Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients","volume":"98","author":"Ishikawa","year":"2007","journal-title":"Cancer Sci"},{"key":"2026100111161357000_vdag233-B13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3171\/2011.4.JNS10377","article-title":"Phase I\/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma: clinical article","volume":"115","author":"Muragaki","year":"2011","journal-title":"J Neurosurg"},{"key":"2026100111161357000_vdag233-B14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3171\/2014.5.JNS132392","article-title":"Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma","volume":"121","author":"Ishikawa","year":"2014","journal-title":"J Neurosurg"},{"key":"2026100111161357000_vdag233-B15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3171\/2022.12.JNS221221","article-title":"A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas","volume":"139","author":"Muragaki","year":"2023","journal-title":"J Neurosurg"},{"key":"2026100111161357000_vdag233-B16","doi-asserted-by":"publisher","first-page":"vdad079","DOI":"10.1093\/noajnl\/vdad079","article-title":"P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients","volume":"5","author":"Yamada","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026100111161357000_vdag233-B17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"2026100111161357000_vdag233-B18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"key":"2026100111161357000_vdag233-B19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00262-020-02551-6","article-title":"Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas","volume":"69","author":"Arolt","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2026100111161357000_vdag233-B20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"key":"2026100111161357000_vdag233-B21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"2026100111161357000_vdag233-B22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-018-0705-7","article-title":"New therapeutic strategies to treat human cancers expressing mutant p53 proteins","volume":"37","author":"Blandino","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2026100111161357000_vdag233-B23","doi-asserted-by":"publisher","first-page":"djv303","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2026100111161357000_vdag233-B24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"2026100111161357000_vdag233-B25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nm.4463","article-title":"Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms","volume":"24","author":"Bezzi","year":"2018","journal-title":"Nat Med"},{"key":"2026100111161357000_vdag233-B26","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2026100111161357000_vdag233-B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2026100111161357000_vdag233-B28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11060-021-03721-x","article-title":"LAG-3 expression in the inflammatory microenvironment of glioma","volume":"152","author":"Mair","year":"2021","journal-title":"J Neurooncol"},{"key":"2026100111161357000_vdag233-B29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"key":"2026100111161357000_vdag233-B30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"2026100111161357000_vdag233-B31","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2026100111161357000_vdag233-B32","doi-asserted-by":"publisher","first-page":"615317","DOI":"10.3389\/fimmu.2020.615317","article-title":"LAG3\u2019s enigmatic mechanism of action","volume":"11","author":"Graydon","year":"2020","journal-title":"Front Immunol"},{"key":"2026100111161357000_vdag233-B33","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1002\/ijc.31661","article-title":"Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma","volume":"143","author":"Harris-Bookman","year":"2018","journal-title":"Int J Cancer"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag233\/70944768\/vdag233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag233\/70944768\/vdag233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag233\/70944768\/vdag233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:18:22Z","timestamp":1790867902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag233\/8782876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag233","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag233"}}